← back to search

Marco Torregroza Otero

Cancer Research Institute ·
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology, and Breast Cancer Treatment Studies.
h-index
7
citations
3,116
works
8
NIH funding
—
primary concept
Medicine
email
✉ Find email ↗

Recent publications

Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355
JNCI Journal of the National Cancer Institute 2023cited by 22position: middledoi
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
New England Journal of Medicine 2022cited by 1,053position: middledoi
LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC
Annals of Oncology 2021cited by 52position: middledoi
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
The Lancet 2020cited by 1,776position: middledoi
KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
Journal of Clinical Oncology 2020cited by 183position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Javier Cortés · Universidade Nova de Lisboa4 papers (2020–2023)David W. Cescon · University Health Network4 papers (2020–2023)Norikazu Masuda · Kyoto University4 papers (2020–2023)Hope S. Rugo · UCSF Helen Diller Family Comprehensive Cancer Center4 papers (2020–2023)Carlos H. Barrios · Centro Brasileiro de Estudos em Dermatologia4 papers (2020–2023)Hiroji Iwata · Juntendo University4 papers (2020–2023)Sherene Loi · Peter MacCallum Cancer Centre4 papers (2020–2023)Mastura Md Yusof · National Cancer Centre Japan4 papers (2020–2023)Seock‐Ah Im · Seoul National University3 papers (2020–2023)Xuan Zhou · University of Edinburgh3 papers (2021–2023)Vassiliki Karantza · Merck & Co., Inc., Rahway, NJ, USA (United States)3 papers (2020–2022)Erhan Gökmen · Universidad de la República de Uruguay3 papers (2020–2023)Carlos Gallardo · Fundación Arturo López Pérez3 papers (2020–2023)Zifang Guo · Beijing Chemical Industry Research Institute (China)3 papers (2020–2023)Peter Schmid · Cancer Research Institute3 papers (2020–2023)Oleg Lipatov · Bashkir State Medical University3 papers (2020–2023)José Manuel Pérez-García · Asociación Española Contra el Cáncer2 papers (2022–2023)Zhikun Guo · Nankai University1 papers (2021–2021)Zbigniew Nowecki · Institute of Cardiology1 papers (2020–2020)Peter Schmid · Institut de Recherche en Cancérologie de Montpellier1 papers (2021–2021)